Publisher's Synopsis
This work highlights the eternal conflict between health for all and the imperative of profitability of intellectual property linked to patents on medicines in the pharmaceutical industry. Health for all is difficult to reconcile with the need for patent profitability. Obtaining a patent for a drug is a long and costly procedure for laboratories. Obtaining it generally rhymes with an obligation of profitability. The expiration of the patent on the drug generates strategies on the part of pharmaceutical companies that are not in the service of health. Does health have a price?
